Oruka Therapeutics, Inc.(ORKA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ORKA Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Oruka Therapeutics, Inc. (ORKA), a Healthcare sector company. ORKA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Oruka Therapeutics, Inc. reports net income of $-41.2M, free cash flow of $-33.1M. Top institutional holders of ORKA by reported 13-F value include FMR, BlackRock, VR Adviser, based on the most recent SEC filings. ORKA trades on the Nasdaq exchange and files with the SEC under CIK 907654. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ORKA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Oruka Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-41.2M
Free Cash Flow
Q2 2026
$-33.1M
ROIC
Q2 2026
-18.0%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-25.9% YoYOperating Income
EPS (Diluted)
Total Assets
+23.4% YoYTotal Debt
Op. Cash Flow
Free Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $-105.4M -25.9% | $-83.7M -1468.2% | $-5.3M +46.2% | $-9.9M +48.6% | $-19.3M -98.4% | $-9.7M |
| Operating Income | $-122.1M | — | $-7.3M +31.1% | $-10.6M +45.2% | $-19.3M -98.0% | $-9.8M |
| EPS (Diluted) | — | — | $-0.37 +46.4% | $-0.69 +50.4% | $-1.39 | — |
| Total Assets | $488.6M +23.4% | $396.0M +946.0% | $37.9M -12.1% | $43.1M -21.6% | $54.9M +8.9% | $50.4M |
| Total Debt | — | — | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Cash Flow | $-88.2M | — | $-5.0M +54.1% | $-10.9M +41.8% | $-18.8M -142.9% | $-7.7M |
| Free Cash Flow | $-88.4M | — | $-5.0M +54.1% | $-10.9M +42.0% | $-18.8M -142.8% | $-7.7M |
Get alerted when ORKA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Oruka Therapeutics, Inc. including:
Top Institutional Holders of ORKA
FMR LLC
$862.0M9,057,645 shBlackRock, Inc.
$474.9M4,990,181 shVR Adviser, LLC
$394.8M4,148,428 shFairmount Funds Management LLC
$352.6M3,705,262 shCapital World Investors
$323.7M3,401,639 shRTW INVESTMENTS, LP
$298.7M3,139,030 shSTATE STREET CORP
$254.4M2,673,090 shVANGUARD CAPITAL MANAGEMENT LLC
$224.7M2,360,971 shParadigm Biocapital Advisors LP
$204.1M2,144,526 shDeep Track Capital, LP
$183.3M1,926,000 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $862.0M | 9,057,645 |
| BlackRock, Inc. | $474.9M | 4,990,181 |
| VR Adviser, LLC | $394.8M | 4,148,428 |
| Fairmount Funds Management LLC | $352.6M | 3,705,262 |
| Capital World Investors | $323.7M | 3,401,639 |
| RTW INVESTMENTS, LP | $298.7M | 3,139,030 |
| STATE STREET CORP | $254.4M | 2,673,090 |
| VANGUARD CAPITAL MANAGEMENT LLC | $224.7M | 2,360,971 |
| Paradigm Biocapital Advisors LP | $204.1M | 2,144,526 |
| Deep Track Capital, LP | $183.3M | 1,926,000 |
More Healthcare Companies
View all Healthcare →Put ORKA on your watchlist
Track score changes the day Oruka Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ORKA a good stock to buy?
13F Pro's AI-powered analysis of Oruka Therapeutics, Inc. (ORKA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ORKA are available on the ORKA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ORKA is classified as a mid company.
Which hedge funds own ORKA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ORKA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Oruka Therapeutics, Inc.'s investment landscape.